Five Oceans Advisors acquired a new stake in GSK plc (NYSE:GSK – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 6,741 shares of the pharmaceutical company’s stock, valued at approximately $293,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Tyler Stone Wealth Management acquired a new position in GSK during the 4th quarter worth approximately $26,000. Tsfg LLC increased its holdings in GSK by 67.9% in the first quarter. Tsfg LLC now owns 618 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 250 shares during the last quarter. Glassman Wealth Services raised its stake in GSK by 71.3% in the fourth quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock valued at $28,000 after buying an additional 261 shares in the last quarter. Toth Financial Advisory Corp purchased a new stake in GSK during the 1st quarter worth about $30,000. Finally, Strategic Asset Management LLC boosted its position in shares of GSK by 119.8% during the 2nd quarter. Strategic Asset Management LLC now owns 734 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 400 shares in the last quarter. 16.86% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on GSK shares. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating in a research note on Thursday, September 8th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a report on Wednesday, September 7th. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. AlphaValue downgraded shares of GSK to a “reduce” rating in a research note on Tuesday, July 19th. Finally, Citigroup reiterated a “neutral” rating on shares of GSK in a research report on Thursday, July 21st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $1,700.00.
GSK Stock Performance
GSK (NYSE:GSK – Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.11. The firm had revenue of $8.71 billion during the quarter, compared to the consensus estimate of $9.35 billion. GSK had a return on equity of 27.84% and a net margin of 12.91%. Equities analysts predict that GSK plc will post 3.23 earnings per share for the current fiscal year.
GSK Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be issued a dividend of $0.383 per share. This is a boost from GSK’s previous quarterly dividend of $0.35. This represents a $1.53 annualized dividend and a yield of 5.23%. The ex-dividend date is Thursday, August 18th. GSK’s dividend payout ratio is currently 50.66%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- What Steelcase’s Earnings Say About the Return to the Office?
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.